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YingWang, Feng Chen, Yue Han, Zheng-Zheng Fu, Xiao-Wen Tang, Miao Miao, Hui-Ying Qiu,
Zheng-Ming Jin, Ai-Ning Sun, De-Pei WuThe optimal alternative donor for adult hematopoietic stem cell transplantation (HSCT) candidates who lack
an ideal histocompatible sibling remains controversial. We studied the clinical outcomes of 88 adult patients
with hematologic malignancies who received a partially matched related donor (PMRD) transplant (n5 36)
or a matched unrelated donor (MUD) transplant (n5 52) with a uniform myeloablative protocol without ex
vivo T cell depletion. Age and other characteristics were comparable in the 2 groups, except that the PMRD
group had a higher proportion of bone marrow (BM) grafts. Primary engraftment was achieved in nearly 98%
of the whole cohort. The incidences of acute grade III-IV and extensive chronic graft-versus-host disease
(aGVHD, cGVHD) were 15% and 16% in the PMRD group and 16% and 14% in the MUD group. Although
treatment-related mortality (TRM) was 42% in the PMRD group and 31% in the MUD group (P5.29), the
relapse rate was\11% for the whole cohort. With a median follow-up of 30 months, no statistically signif-
icant differencewas observed in 3-year overall survival (OS) and event-free survival (EFS) between the PMRD
group (45% and 38%) and the MUD group (54% and 50%). These data demonstrate that HSCT performed
with PMRD can be an alternative option for treating adult patients with hematologic malignancies.
Biol Blood Marrow Transplant 15: 1258-1264 (2009)  2009 American Society for Blood and Marrow TransplantationKEY WORDS: Partially matched related, Unrelated, Hematopoietic stem cell transplantation, Hematologic
malignancyINTRODUCTION
Allogeneic hematopoietic stem cell transplantation
(HSCT) is a potentially life-saving treatment for many
hematologic malignancies. But, for patients lacking an
ideal histocompatible sibling, the choice of the best
alternative donor remains a matter of debate, because
of the lack of data on outcomes from randomized con-
trolled trials involving matched unrelated donor
(MUD), umbilical cord blood (UCB), and partially
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6/j.bbmt.2009.05.020For adults, transplantation using UCB has not yet
been widely accepted because of concerns about the
lownumber of stem cells present in graft collections, al-
though transplantation of 2 units shows promise [6,7].
PMRD transplants have several advantages over
MUD transplants, including immediate availability
for virtually all patients (particularly important for
those requiring urgent transplantation), significant
cost savings, the ability to select the best donor among
all relatives, optimal graft composition, and the avail-
ability of donor lymphocyte infusion (DLI) after trans-
plantation if necessary [8].
Work on PMRD transplants has been ongoing for
more than 20 years. Early experiences indicated infe-
rior overall survival (OS) associated with transplanta-
tion of PMRD grafts compared with MUD grafts
[9,10]. A study of 129 patients who received a MUD
or PMRD transplant found a significantly better
2-year OS in the MUD group (58% vs 21%;
P5 .002) [10]. Since that time, however, significant
improvements in conditioning regimens and graft
manipulations have resulted in substantially improved
outcomes for PMRD HSCT [8]. Impressive survival
Table 1. Characteristics of patients and grafts
Characteristic
PMRD
Grafts
MUD
Grafts P
Recipients, n 36 52
Median age, years (range) 24 (18-47) 26 (18-49) .516
Sex, male/female 21/15 39/13 .099
Diagnosis .281
Acute myelogenous leukemia 8 15
Acute lymphocytic leukemia 13 22
Chronic myelogenous leukemia 11 14
Non-Hodgkin lymphoma 4 1
Disease status .186
CR with low risk 14 23
CR with high risk 18 28
Refractory/relapsed 4 1
Graft type <.001
PBSCs alone 0 45
BM alone 23 7
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scale reports, and conflicting data against the inferior
outcome of PMRD transplant also have surfaced
[5,11-13]. Making a conclusive decision regarding
transplant type remains difficult, because of the het-
erogeneity of the patient populations and regimens
used in different studies. Controversy about the rela-
tivemerits of PMRD versusMUDpersists, and further
research is warranted.
In this study, we retrospectively analyzed data on
adult patients who underwent HSCT in our center
between 2003 and 2008 with either a PMRD or
MUD transplant after myeloablative (MA) condition-
ing, to assess the impact of donor source on clinical
outcomes.BM + PBSCs 13 0
Cell dose
CD34+ 106/kg 5.7 (3.4-9.3) 4.9 (2.4-18.3) .714
CD3+ 107/kg 9.6 (2.9-36.7) 29.6 (10.7-62.3) <.001
PMRD indicates partially matched related donor; MUD, matched unre-
lated donor; CR, complete remission; PBSCs, peripheral blood stem
cells; BM, bone marrow.
Table 2. Characteristics of PMRD graft recipients
Characteristic Quantity
Recipients, n 36
Donor/recipient relationship
Mother/child 23 (63.9%)
Father/child 1 (2.8%)
Child/mother 2 (5.6%)
Child/father 4 (11.1%)
Siblings 6 (16.7%)
HLA disparity in the graft-versus-host
direction at HLA-A, -B, and -DR
1 1 (2.8%)
2 16 (44.4%)
3 19 (52.8%)
PMRD indicates partially matched related donor.PATIENTS AND METHODS
Patients
A total of 88 consecutive patients aged. 18 years
who underwent PMRD (n 5 36) or MUD (n5 52)
HSCT for a hematologic malignancy with a uniform
protocol in our Hematology Department between
July 2003 and June 2008 were enrolled in this study.
All patients and donors provided written informed
consent for the protocol, which was approved by our
hospital’s Ethics Committee. Patient characteristics
are summarized in Table 1. Patients in complete re-
mission (CR) with high risk included those with acute
leukemia with unfavorable cytogenetic data at diagno-
sis, secondary leukemia, in second or further remis-
sion, and chronic myelogenous leukemia (CML) not
in the first chronic phase (CP). Patients with other dis-
eases were considered to be at standard risk. More in-
formation on the donor–recipient relationships and
HLA disparities in the PMRD group is provided in
Table 2.
HLATyping
HLA-A, -B, -C, and -DRB1 typing of the recipi-
ents and unrelated donors were performed by high-
resolution DNA typing techniques using polymerase
chain reaction (PCR) with sequence-specific primers.
PMRD grafts were typed at low resolution for HLA-
A, -B and –DR. For comparison of HLA matching
between partially matched related pairs, the high-
resolution HLA data of the recipients were converted
to low-resolution equivalents.
Conditioning
Patients with myelogenous leukemia received
a conditioning regimen consisting of cytarabine 4 g/
m2/day (on days 210 and 29), busulfan (Bu) 3.2 mg/
m2/day i.v. (on days 28 to 26), cyclophosphamide
(Cy) 1.8 g/m2/day (on days 25 to 24), semustine
250 mg/m2/day (on day23), and rabbit antithymocyteglobulin (ATG; Genzyme, Cambridge, MA) 2.5 mg/
kg/day (on days 25 to 22). Patients with acute lym-
phoblastic leukemia (ALL) or non-Hodgkin lym-
phoma (NHL) received a similar regimen, but with
total body irradiation (TBI; 8 Gy, lung shielding at
6.5 Gy, on day -6) substituted for Bu and cytarabine
started on day -8.Graft-versus-Host Disease Prophylaxis
Graft-versus-host disease (GVHD)prophylaxis con-
sistedof continuous cyclosporine (CsA) infusion at 3 mg/
kg/day starting on day -10, mycophenolate mofetil
(MMF) 1.0 g/day from days -10 to 130, and short-
term methotrexate (MTX) given on days 11, 13, 16,
and 111 at doses of 15, 10, 10, and 10 mg/m2,
respectively.
The onset and grades of acute and chronic GVHD
(aGVHD, cGVHD) were assessed according to pub-
lished consensus criteria [14,15]. The first-line treat-
ment for aGVHD was based on the administration
1260 Biol Blood Marrow Transplant 15:1258-1264, 2009Y. Wang et al.of methylprednisolone 2 mg/kg/day in the event that
grade$ II aGVHD developed.
Hematopoietic Stem Cell Collection and
Supportive Care
Donors were primed with granulocyte colony-
stimulating factor (G-CSF) injected s.c. at a dose of
300 mg/day for 5 consecutive days before stem cell har-
vesting. PMRD recipients received bone marrow (BM)
or BM plus peripheral blood stem cells (PBSCs) if the
number of CD341 cells in the BM harvest
was\3.0 106 cells/kg. No extra manipulation was
produced to the inoculum before infusion, except to
remove red cells and plasma in cases of ABO incompat-
ibility.
All patients received cytomegalovirus (CMV) pro-
phylaxis with ganciclovir for 10 days before transplan-
tation and an s.c. injection of G-CSF 300 mg starting
on day 7 until the absolute neutrophil counts (ANCs)
were. 0.5 109/L. Standard prophylactic antibiotics
were administered in accordance with institutional
guidelines.
DLI
Patients with relapse, persistent minimal residual
disease, or decreased donor chimerism with no re-
sponse to immunosuppressive drug alteration were
candidates for DLI therapy. Cells were from cryopre-
served PBSCs for unrelated recipients. PMRD recipi-
ents received newly G-CSF–mobilized PBSCs.
Endpoints and Definitions
Outcome was documented in terms of engraft-
ment, GVHD, treatment-related mortality (TRM),
relapse, OS, and event-free survival (EFS). Time to en-
graftment was assessed according to standard criteria,
with donor cell engraftment determined on marrow
samples of recipients using quantitative PCR of infor-
mative short tandem repeat regions. Graft failure was
defined as failure to achieve and maintain a neutrophil
count. 0.5 109/L. TRM was defined as death in
continuous CR; OS, as the time interval from the
date of transplantation to the date of death; and EFS,
as the time from transplantation to treatment failure
(death or relapse).
Statistical Analysis
Comparisons of patient characteristics were per-
formedusing thec2 orFisher’s exact test for categorical
variables and the Mann-Whitney test for continuous
variables. Cumulative incidence curves were used to
calculate the probability of aGVHD, using TRM and
relapse as competing risks. The probability of OS and
EFS were estimated using the Kaplan-Meier method
and compared using the log-rank test. Prognostic
factors for OS and EFS (all baseline variables listed inTable 1) were examined in the Cox proportional haz-
ards model. All statistical analyses conducted were
based on data available on January 31, 2009, and per-
formedwith SPSS version 11.0. AllP values are 2-sided.
Results were considered statistically significant when P
\ .05.RESULTS
Engraftment
Of the 88 patients in the cohort, 87 were evaluable
for engraftment; 1 MUD recipient died 2 days after
HSCT of sepsis-associated multiple-organ failure.
Two patients in the PMRD group, 1 with refractory
acute myelogenous leukemia (AML) and 1 with
relapsed ALL at transplantation, demonstrated disease
progression before achieving this endpoint. All other
patients achieved neutrophil engraftment. The per-
centage of patients achieving engraftment did not dif-
fer significantly between the 2 groups (P 5 .17). The
median time to neutrophil recovery was 12 days
(range, 10 to 20 days) in the PMRD group and 13
days (range, 11 to 19 days) in the MUD group. The
median time to recovery of platelet counts
of. 20 109/L was 19 days (range, 13 to 42 days).
Three patients in PMRD group who died before
achieving full platelet engraftment were excluded
from the analysis. There was no statistically significant
difference in the speed of platelet engraftment between
the 2 groups. One patient in PMRD group experi-
enced later graft failure on day 45, but subsequently
achieved durable engraftment after receiving DLI.
Analysis of DNA polymorphism confirmed complete
donor chimerism of all of the patients after hematopoi-
etic recovery.GVHD
As shown in Figure 1, of the 85 patients evaluable
for GVHD, the cumulative incidence of grade II-IV
aGVHD at 100 days in patients who received PMRD
grafts was 41% (95% confidence interval [CI], 25%
to 58%), and 33% for those who received MUD grafts
(95% CI, 20% to 46%) (P 5 .34). The incidence of
grade III-IV aGVHD was 15% in the PMRD group
and 16% in the MUD group. The proportion of pa-
tients with steroid-refractory aGHVD was 39% for
the whole cohort.
In 69 patients (25 PMRD, 44 MUD) surviving and
in remission beyond day 100, the cumulative risk of de-
veloping cGVHD was 48% (95% CI, 28% to 68%) in
the PMRD group and 32% (95% CI, 18% to 46%) in
the MUD group (P 5 .18). Although the rate of
cGVHD was slightly higher in the PMRD group
than in the MUD group, the incidence of extensive
Figure 1. Cumulative incidence of grade II-IV acute GVHD according
to donor type.
Figure 2. The probability of 3-yearOS (A) and EFS (B) according to do-
nor type.
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vs 14%, P 5 .99).
TRM and Relapse
A total of 31 patients died because of TRM, which
included infections (n5 18), GVHD (n5 11), and
other toxicities (n5 2), resulting in a rate of 42%
(95% CI, 26% to 58%) in the PMRD group and
31% (95% CI, 18% to 44%) in the MUD group. In-
fection contributed to the majority of deaths in the
whole cohort (18 of 31 deaths; 58%), but nearly all
of these patients had ongoing GVHD or were receiv-
ing immunosuppressive therapy for GVHD preven-
tion.
Nine patients (4 in the PMRD group and 5 in the
MUD group) had relapsed by the time of the last
follow-up. Of note, all 4 of the patients in the
PMRD group received DLI; of these, 2 patients
achieved CR, 1 patient is still alive in CR for 6 months,
and 1 patient died of a second relapse 2 years later.
Survival
The median follow-up time for the whole cohort
was 30 months (range, 6 to 67 months). That for the
PMRD group was 42 months (range, 6 to 67 months),
and that for the MUD group was 27 months (range, 6
to 66 months). Overall, 39 patients died. The esti-
mated probability of OS at 3 years after HSCT was
50% for the whole cohort (45% for the PMRD group
vs 54% for the MUD group; P5 .11). Likewise, the
3-year probability of EFS did not differ significantly
between the 2 groups (38% for the PMRD group vs
50% for the MUD group; P5 .12) (Figure 2). These
results were confirmed in a multivariate regression
model (Table 3). Because mothers accounted for the
majority of the donors in the PMRD group, we also
calculated the survival rate of this cohort. Notably,
although 13 of these patients (57%) belonged to
the high-risk group, the 3-years OS was 52% and the
3-year EFS was 49%, similar to the rates for the
MUD group.DISCUSSION
This retrospective single-center study compara-
tivelyanalyzedtransplantationoutcomesinaconsecutive
series of adult patients who underwent myeloablative
(MA) allogeneicHSCT in a uniform fashion from either
matched unrelated or HLA-disparate family donors.
Our data confirm that the outcomes of HSCT per-
formed with PMRD grafts are comparable to those of
HSCT performed with MUD grafts.
Both T cell–replete and T cell–depleted (TCD)
strategies have been evaluated in an effort to overcome
the complications after mismatched related HSCT
[16]. Unmanipulated graft transplantation has at least
2 advantages over the in vitroTCDapproach: (1) easier
to perform and less expensive, and (2)more rapid donor
T cell recovery, which is crucial to provide a tangible
graft-versus-leukemia effect for patients with advanced
malignancies [12,17]. Distinct from early clinical
experiencewithTcell–repleteHSCTwith a significant
incidence of GVHD [18], the incidence of serious
a GVHD was kept\20% with proper pharmacologic
prophylaxis in our study, in agreement with incidences
reported by other authors [5,11].
The rates of serious aGVHD and extensive
cGVHD were very similar in the 2 groups (15% and
16% in PMRD group vs 16% and 14% in MUD
group), although the rates of severe aGVHD and
cGVHD were slightly higher in the PMRD group.
Table 3. Multivariate analysis of factors associated with OS
and EFS
OS EFS
Parameter
Hazard ratio
(95% CI) P
Hazard ratio
(95% CI) P
Age
# median 1 .11 1 .37
> median 1.04 (0.99-1.09) 1.02 (0.98-1.07)
Donor–recipient sex
pair
Female-to-male 1 .39 1 .30
Other combinations 0.75 (0.39-1.44) 0.71 (0.37-1.35)
Disease status
Low 1 .04 1 .07
High 2.05 (1.02-4.14) 1.85 (0.95-3.63)
Graft type
BM only 1 .82 1 .92
With PBSCs 0.91 (0.40-2.07) 1.05 (0.46-2.36)
Donor type
PMRD 1 .08 1 .18
MUD 0.25 (0.05-1.17) 0.36 (0.08-1.61)
OS indicates overall survival; EFS, event-free survival; BM, bonemarrow;
PBSCs, peripheral blood stem cells; PMRD, partially matched related do-
nor; MUD, matched unrelated donor.
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PMRD group received G-CSF–primed BM grafts
may have contributed to a protective effect. Previous
studies have found that G-CSF priming significantly
increased the number of CD341 cells, reduced the
number of total lymphocytes, and reversed the
CD41:CD81 ratio in the donor marrow [19,20].
Thus, G-CSF–primed BM may offer some or all of
the benefits of PBSCs, whereas avoiding the risks of
PBSCs. Given the pain associated with BM harvest
and the risk of anesthesia in the procedure, this charac-
teristic is an inherent advantage of PMRD grafts, as is
the feasibility of obtaining additional donor cells for
immunotherapy after transplantation. Nevertheless,
this advantage of primed BM failed to improve patient
outcomes in multivariate analysis (Table 3), indicating
that stem cell source actually may not be a prognostic
factor for survival [11,21].
The other potential explanation for the low
incidence of serious GVHD in the PMRD group is
the administration of a combination of ATG and other
immunosuppressive agents. This combination pro-
vides sufficient immunosuppression to offset the dis-
advantage of HLA disparity. Recent findings have
demonstrated that ATG, a polyclonal antibody target-
ing a broad range of T cells, has diverse immunomod-
ulatory activities beyond T cell depletion, suggesting
a positive role in immune recovery after transplanta-
tion [22]. Furthermore, relapse rates as low as 11%
in our study and other studies indicate that ATG
does not influence the antitumor effect [11,13]. Lu
et al. [11] reported an estimated risk of relapse at 2
years of 14% in patients receiving a PMRDgraft, com-
pared with 13% in those receiving a matched siblinggraft without ATG administration. Beyond ATG,
some novel potent immunosuppressive agents, such
as alemtuzumab and sirolimus, are now available
[23], and preliminary data suggest exciting results in
this context [24,25].
In our study, the 3-year EFS for the PMRD group
of 38% is slightly worse than that reported by the Bei-
jing group of Lu et al. [11] using an almost-identical
regimen. In addition to the heterogeneity of the
patient age and disease composition, we also note
that the Beijing group used grafts with a small BM
harvest (median CD341 cell dose, 2.3 106/kg).
Megadose CD341 cells are known to have veto activity
in the TCD setting, which might affect transplant out-
comes [26]. Whether or not this factor might contri-
bute to the discrepancy between the 2 centers in
non-TCD matters awaits further study.
It should be noted that even though the difference
in long-term survival did not reach statistical signifi-
cance between our 2 groups, a slight trend toward
higher mortality mainly resulting from TRM after
PMRDtransplantationwas found to exist. Fortunately,
several measures to counteract the disadvantage of
HLA mismatching may be available in the near future.
In our practice, if a patient is eligible for allogeneic
HSCT, but has no matched related donor, then we
generally wait for the results of an MUD search first,
rather than considering PMRD transplantation imme-
diately. In fact, the time from diagnosis to transplanta-
tion has been shown to be a negative prognostic factor
[3]. Thus, to decrease the accumulation of chemother-
apy-induced toxicity and likelihood of disease progres-
sion, it might be appropriate to consider PMRD
HSCT as an initial treatment in patients requiring
urgent transplantation.
Another important way to decrease TRM is to use
reduced-intensity conditioning (RIC). After its extraor-
dinary success in MUDHSCT, RIC is currently being
explored as an option in PMRD transplantation in se-
lected patients [27]. In one of the largest series to date,
49 adult patients who received an unmanipulated
PBSC transplant after RIC consisting of alemtuzumab,
fludarabine (Flu), andCyhadaTRMrate of only 10.2%
and a 1-year OS for standard-risk patients of 63% [17].
Burroughs et al. [5] reported the outcomes of 28 pa-
tients with refractory or relapsed Hodgkin lymphoma
(HL) who received a haploidentical transplant using
a different conditioning regimen. Compared with
HLA-matched related recipients, the haploidentical
transplant recipients had a significantly lower TRM
(hazard ratio, 0.14; 95% CI, 0.0 to 0.7; P5 .02) and
better 2-year progression-free survival (PFS). For
high-risk patients, conclusions based on these results
should still be viewed with caution, however.
In the present study, we found that patients receiv-
ing a mother donor transplant had a relatively better
outcome, with a 3-year OS of 52%. Although our
Biol Blood Marrow Transplant 15:1258-1264, 2009 1263Partially Matched Related HSCT in Adult Patientslow patient numbers does not allow us to draw any firm
conclusions, these data may support the hypothesis
that a better survival can be expected in patients
receiving maternal grafts. It has been proposed that,
in both T cell–replete and TCD circumstances,
patients receiving a maternal graft had better survival
than those receiving a paternal graft [28,29]. This dis-
crepancy is speculated to be the result of a confronta-
tion between the immune systems of mother and
offspring during pregnancy, leading to immunologic
hyporesponsiveness (decreased GVHD hazard) or
immunologic sensitization (enhanced graft-versus-
leukemia effect) [28,29]. Contradictory results also
have been reported, however [11,30]. In fact, many
other donor factors (e.g.,degree of HLA incompatibil-
ity, natural killer cell alloreactivity, age, female donor
for male patients, CMV status) have been associated
with outcome in separate studies, but have not been
addressed in a comprehensive fashion [3,4,31,32].
A large-scale study to generate an applicable scoring
system based on these variables can help determine
the most appropriate donor selection.
In conclusion, within the limitation of a retrospec-
tive study, we have demonstrated that HSCT with
PMRD grafts without ex vivo TCD may not compro-
mise outcome compared with HSCT with MUD
grafts. In light of continuous improvements in trans-
plantation technology, performing PMRD HSCT in
a subset of patients lacking a HLA-matched sibling
donor is an acceptable choice.ACKNOWLEDGMENTS
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